Clinical trials: H1N1/Influenza Infection
H1N1 Influenza
Antibody Production Following H1N1 Influenza Vaccination After Stem Cell and Heart Transplantation
Stem cell and and heart transplant patients will receive pandemic H1N1 influenza vaccination according to the clinical guidelines. In these patients the investigators will measure the specific antibody production.
- Trial name
- NCT01008683
- Where
- Israel
- Volunteers
- 300 people
- Sponsor
- Hadassah Medical Organization
Influenza
Sinovac, Pandemic Influenza A/H1N1 Vaccine in 6 to 35 Months Infants
A single center, observer-masked, randomized clinical trial is to be conducted in 6-35 months infants to evaluate the safety and immunogenicity of Sinovac's influenza A/H1N1 Vaccine (PANFLU.1).
- Trial name
- NCT01047202
- Testing
- Pandemic influenza A/H1N1 vaccine, Seasonal trivalent vaccine
- Where
- China
- Volunteers
- 310 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Influenza, Swine-Origin A/H1N1 Influenza Virus
Post Authorization Safety Study of the Pandemic A/H1N1 Influenza Vaccines in Children and Adults
This study is designed to assess the safety of the approved and licensed HUMENZA (adjuvanted A/H1N1 pandemic influenza vaccine) and PANENZA (non-adjuvanted A/H1N1 pandemic influenza vaccine) to meet regulatory requirements for…
- Trial name
- NCT01032980
- Where
- 5 sites in France
- Volunteers
- 3,934 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza, Human
Safety Study to Assess IV Zanamivir for Treatment of Influenza Infection in Patients Who Are in Hospital
The purpose of this study is to determine whether zanamivir aqueous solution given by intravenous injection is safe in treating hospitalized patients with confirmed influenza infection.
- Trial name
- NCT01014988
- Testing
- zanamivir aqueous solution
- Where
- 110 sites in United States, Australia and 11 more
- Volunteers
- 202 people
- Sponsor
- GlaxoSmithKline
Influenza
A Study to Evaluate Safety and Immunogenicity of FluvalAB-like Influenza Vaccine in Non-Elderly Adult and Elderly Subjects
The purpose of this study is to determine the immunogenicity and tolerability of one 0.5 mL intramuscular (IM) injection of FLUVAL AB-like trivalent influenza vaccine containing 6μgHA of seasonal A/H1N1, A/H3N2 and B influenza…
- Trial name
- NCT01459276
- Testing
- Vaccination with FAB-6011, Vaccination with FluvalAB
- Where
- 7 sites in Hungary
- Volunteers
- 1,206 people, healthy volunteers welcome
- Sponsor
- Fluart Innovative Vaccine Ltd, Hungary
Influenza
Study to Evaluate Safety and Immunogenicity of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Children
The purpose of this study is to assess the safety and immunogenicity of two doses of the H1N1 candidate vaccine administered in children aged between 8 and 12 weeks at the time of first vaccination.
- Trial name
- NCT01003418
- Testing
- GSK2340272A GSK Biologicals' investigational influenza pandemic vaccine, Infanrix™-IPV/Hib, Prevenar
- Where
- 4 sites in Norway
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Respiratory Syncytial Viruses
The Respiratory Protection Effectiveness Clinical Trial
Despite widespread use of respiratory protective equipment in the U.S. healthcare workplace, there is very little clinical evidence that respirators prevent healthcare personnel (HCP) from airborne infectious diseases.
- Conditions
- Influenza, Respiratory Syncytial Viruses, Paramyxoviridae Infections, Coronavirus
- Trial name
- ResPECT (NCT01249625)
- Testing
- N95 Respirator, Medical/surgical mask
- Where
- 7 sites in United States
- Volunteers
- 2,862 people
- Sponsor
- Johns Hopkins University
Influenza
A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Adults in the USA
The purpose of this study is to determine whether CSL425 is a safe and effective vaccine for eliciting an immune response to H1N1 influenza in healthy adults
- Trial name
- NCT00958126
- Testing
- CSL425
- Where
- 11 sites in United States
- Volunteers
- 1,313 people, healthy volunteers welcome
- Sponsor
- Seqirus
Rheumatoid Arthritis, Spondyloarthritis
Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases
The prognosis of rheumatic diseases has improved considerably with development of therapy. However, infections are considered the most important cause of morbidity and mortality in this group of patients.
- Conditions
- Rheumatoid Arthritis, Spondyloarthritis, Systemic Lupus Erythematosus (SLE), Dermatomyositis (DM)
- Trial name
- NCT01151644
- Testing
- Anti-pandemic H1N1 influenza vaccine
- Where
- Brazil
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo
2009 H1N1 Influenza
Effect of Age and Prior Immunity on Response to H1N1 Vaccines in Children
A total of 51 children between the ages of 4 and 9 will be randomized to receive a two dose schedule of either licensed live attenuated A/California/07/09 influenza vaccine (LAIV) or licensed inactivated A/California/07/09…
- Trial name
- H1N1Children (NCT01097941)
- Testing
- Live Attenuated H1N1 Influenza Vaccine, Influenza A (H1N1) 2009 Monovalent Vaccine, Influenza A (H1N1) 2009 Monovalent Vaccine/ Influenza A (H1N1) Monovalent Vaccine Live
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Rochester
Novel (H1N1) Influenza
Virus Shedding and Environmental Deposition of a Novel Influenza Virus
An influenza pandemic has recently been declared, involving the novel A(H1N1) 'swine flu' virus. This has spread to almost 100 countries worldwide in less than two months, causing widespread disease so far in Mexico, USA and…
- Trial name
- NCT01046734
- Where
- 3 sites in United Kingdom
- Volunteers
- 105 people
- Sponsor
- University of Nottingham
Clinically Suspected H1N1 Infection
Influenza A H1N1: Retrospective Analysis of PCR Confirmed Cases of H1N1 Infections in Styria - Risk Factors, Clinical Features and Outcome.
This retrospective study will analyse all PCR-proven H1N1 cases from the influenza season 2009/2010 treated within the styrian "LKH hospital network".
- Trial name
- NCT01343979
- Where
- Austria
- Volunteers
- 800 people
- Sponsor
- Medical University of Graz
Influenza A Virus Infection
Antiviral Therapy for Influenza A H1N1
The aims of this study are to characterise the clinical efficacy and virological clearance dynamics of orally administered oseltamivir in patients with influenza caused by novel influenza A(H1N1).
- Trial name
- SEA032 (NCT00985582)
- Where
- Vietnam
- Volunteers
- 181 people
- Sponsor
- South East Asia Infectious Disease Clinical Research Network
Influenza
Influenza Challenge Study of VIS410 in Healthy Volunteers
A phase 2 a study to assess the safety profile and the effect of VIS410 in healthy subjects after inoculation with influenza A virus (H1N1).
- Trial name
- NCT02468115
- Testing
- VIS410
- Where
- Belgium
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Visterra, Inc.
Influenza A Virus, H1N1 Subtype, Novel Swine-Origin
VRC 308: An Open-Label Phase I Study of the Safety and Immunogenicity of an Investigational H1 DNA Influenza Vaccine, VRC-FLUDNA057-00-VP, in Healthy Adults 18-70 Years Old
Background: Vaccines are substances used to try to create resistance (or immunity) to a disease and to prevent an infection. Researchers are testing a new DNA vaccine designed for a new type of influenza, often referred to as…
- Trial name
- NCT00973895
- Testing
- VRC-FLUDNA057-00-VP
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in a Healthy Pediatric Population in the USA
The purpose of this study is to evaluate the immunogenicity and safety profile of CSL425 (CSL's 2009 H1N1 influenza vaccine) in a healthy pediatric population.
- Trial name
- NCT00958243
- Testing
- CSL's 2009 H1N1 Influenza Vaccine (CSL425)
- Where
- 13 sites in United States
- Volunteers
- 473 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza
A Clinical Trial With Influenza A/H1N1 Vaccines
A single center, stratified, randomized and double-blind phase IV clinical trial is to be conducted in healthy elders (equal to or more than 61 years), adults (18-60 years), adolescents (12-17 years) and children (3-11 years) to…
- Trial name
- NCT00956111
- Testing
- split-virion, adjuvanted H1N1 vaccine of 7.5 μg per dose, split-virion, adjuvanted H1N1 vaccine of 15 μg per dose, split-virion, non-adjuvanted H1N1 vaccine of 15 μg per dose
- Where
- China
- Volunteers
- 1,614 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Influenza
Efficacy of FLU-v in an H1N1 Influenza Human Challenge Model
FLU-v is a broad spectrum influenza vaccine that targets regions conserved among multiple influenza strains. FLU-v adjuvanted with Montanide ISA-51 was shown to be safe in previous trials.
- Trial name
- NCT03180801
- Testing
- adjuvanted FLU-v, Influenza challenge
- Where
- United Kingdom
- Volunteers
- 153 people, healthy volunteers welcome
- Sponsor
- PepTcell Limited
Influenza
Safety and Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (H1N1) (GSK2340272A)
This trial is designed to assess the safety and immunogenicity of a prime-boost schedule of GSK Biologicals' investigational vaccine GSK2340272A in children aged between 3 and 17 years.
- Trial name
- NCT00964158
- Testing
- Pandemic influenza vaccine GSK2340272A
- Where
- 5 sites in Spain
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Novartis H1N1 Vaccine in Pregnant Women
The purpose of this study is to evaluate the safety of a 2009 H1N1 influenza vaccine in pregnant women and to determine how their body reacts to different strengths of the vaccine.
- Trial name
- NCT00992719
- Testing
- Inactivated H1N1 Vaccine
- Where
- 6 sites in United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)